Weinrauch LA, Liu J, Segal AR, Woodward J, et al. SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis. J Diabetes Complications 2020 Oct 7:107761. doi: 10.1016/j.jdiacomp.2020.107761.
PMID: 33234402